Varsha Rathore | Cancer Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Varsha Rathore | Cancer Biology | Best Researcher Award

Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100233 | Taiwan

Dr. Varsha Rathore’s research focuses on elucidating the molecular mechanisms underlying cancer cell migration, invasion, and survival, with a particular emphasis on the role of CASK (Calcium/Calmodulin-dependent Serine Protein Kinase) in prostate cancer progression. Her doctoral work explores how CASK promotes tumor cell motility and invasiveness independent of TGF-Ξ² signaling, contributing to a deeper understanding of tumor metastasis. Additionally, she investigates the involvement of NLRX1 in regulating proliferation, invasion, and survival pathways in prostate cancer cells, offering insights into novel therapeutic targets for cancer treatment. Her expertise spans cell culture, molecular biology, and biochemical assays, including protein expression, purification, ubiquitination, kinase, and PARylation assays, as well as metabolic analysis using Seahorse technology. She has presented her findings at international conferences, including the 19th World Congress of Basic and Clinical Pharmacology and the 38th Joint Academic Conference on Biomedicine. Through her research, Dr. Rathore contributes significantly to the field of molecular oncology and pharmacology, advancing knowledge on how signaling proteins orchestrate cancer progression and identifying potential molecular targets for therapeutic intervention.

Profile: Orcid

Featured Publications:

Rathore, V., Cheng, C.-Y., Lin, C.-Y., Chang, C.-R., & Lin, W.-W. (2025). CASK promotes prostate cancer progression via kinase-dependent activation of AKT. International Journal of Biological Macromolecules, 311(Pt 2), 143965.

Rathore, V., & Lin, W.-W. (2025). Decoding SIGLEC12 in bladder cancer: In silico profiling of expression, tumor–immune interactions, and prognostic impact. Medicina, 61(11), 1894.

Mishra, M., Rathore, V., Sahu, S., & Sahoo, H. (2019). The contribution of nanostructures towards the wing patterning of yellow Catopsilia pomona: How it differs from the lime. Microscopy, 68(4), 289–300.

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-Ξ²-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Alexander Tsankov | Cancer Cell Biology | Best Researcher Award

Icahn School Of Medicine At Mount Sinai | United States

Alexander Tsankov is a leading researcher in computational biology and cancer genomics, known for his contributions to single-cell and spatial transcriptomics. He holds dual bachelor’s degrees in Plan II Honors and Electrical and Computer Engineering from the University of Texas at Austin, and earned his M.S. and Ph.D. in Electrical Engineering and Computer Science from MIT. His research focuses on understanding the cellular and molecular mechanisms underlying cancer progression and tissue remodeling, with an emphasis on glioblastoma, lung adenocarcinoma, and colorectal cancer. Dr. Tsankov has published extensively in top-tier journals such as Nature, Nature Communications, Cancer Discovery, Nature Genetics, and Immunity. He has authored over 50 peer-reviewed publications, with an h-index of 36 and more than 15,000 citations according to Google Scholar. His work has earned him several prestigious honors, including the NIH NRSA postdoctoral fellowship and the NSF graduate fellowship. Dr. Tsankov frequently serves as a senior or corresponding author, highlighting his leadership in the field of computational oncology and single-cell genomics.

Profile: Google Scholar

Featured Publications:

  • “Learning the cellular origins across cancers using single-cell chromatin landscapes”

  • “Cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma”

  • “Single cell profiling of human airway identifies tuft-ionocyte progenitor cells displaying cytokine-dependent differentiation bias in vitro”

  • “Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma”

  • “Glioblastoma shift from bulk to infiltrative growth is guided by plexin-B2-mediated microglia alignment in invasive niches”

  • “Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer”

  • “NOTCH1 drives sexually dimorphic immune responses in hepatocellular carcinoma”

  • “Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations”

  • “Single cell view of tumor microenvironment gradients in pleural mesothelioma”

  • “Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines”

Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Published on by Cell Biologist

Prof. Dr. Yavuz Tekelioğlu | Cancer Cell Biology | Best Academic Researcher Award

Prof. Dr. Yavuz Tekelioğlu | Karadeniz Technical University | Turkey

Prof. Dr. Yavuz Tekelioğlu is a distinguished professor at Karadeniz Technical University’s Faculty of Medicine, specializing in histology, embryology, and toxicology. He has built a prolific academic career focused on cellular and tissue analysis using advanced methods like flow cytometry. Since beginning as a research assistant, he has steadily advanced through academic ranks, culminating in a full professorship. He has supervised numerous theses, contributing significantly to training future scientists. His research emphasizes the protective effects of antioxidants and stem cell therapies on tissue toxicity, with over 100 peer-reviewed publications. Active in professional societies, he also provides comprehensive educational instruction in medicine and dentistry. Prof. Tekelioğlu is committed to advancing biomedical research, particularly in reproductive and hepatic toxicology, through innovative experimental approaches.

Publication Profile:

Scopus

Education:

Prof. Dr. Yavuz Tekelioğlu completed his higher education at Karadeniz Technical University, where he earned his PhD after serving as a research assistant. His academic foundation is firmly rooted in medical sciences, with a focus on histology and embryology. During his doctoral studies, he developed expertise in experimental toxicology and cellular biology, particularly utilizing flow cytometry for immunophenotyping. His training includes specialized certifications in scientific research ethics, flow cytometry techniques, and institutional educational management. These credentials equip him to conduct rigorous, ethical research and provide effective academic leadership. Continuous participation in national and international workshops and symposiums reflects his commitment to staying current with cutting-edge methodologies and ethical standards in biomedical research.

Experience:

Starting as a research assistant, Prof. Tekelioğlu quickly advanced to PhD research assistant, assistant professor, associate professor, and finally full professor at Karadeniz Technical University. Over more than three decades, he has taught histology and embryology to medical, dental, and graduate students while supervising numerous theses on tissue toxicity and protective agents. He has led multiple TÜBΔ°TAK and university-funded projects focusing on mesenchymal stem cells and toxicological evaluations using flow cytometry and histopathology. His academic service extends to practical flow cytometry training, contributing to capacity building in biomedical research. His administrative roles include coordinating research ethics training and educational management. He is a member of prominent scientific societies, contributing to Turkey’s scientific community. His career demonstrates dedication to both research and education.

Research Focus:

Prof. Dr. Tekelioğlu’s research primarily focuses on the histopathological and immunological effects of toxic agents on reproductive and hepatic tissues. His work extensively explores the protective roles of antioxidants like vitamin E, lycopene, beta-glucan, and Coenzyme Q10 against methotrexate-induced toxicity. Employing flow cytometry, histology, and biochemical assays, his studies provide mechanistic insights into cellular apoptosis, oxidative stress, and tissue regeneration. He investigates mesenchymal stem cells for their therapeutic potential in tissue repair and immunomodulation. His experimental models often include rats and mice, enabling controlled studies of drug-induced organ damage and protective interventions. By bridging toxicology with cellular analysis, his research contributes to safer clinical drug use and novel treatment strategies. Additionally, his recent work on ovarian and cardiac protection highlights translational relevance. His interdisciplinary approach combines toxicology, reproductive biology, and flow cytometry, establishing him as a leader in biomedical research.

Publication Top Notes:Β 

  • Coenzyme Q10 may protect ovarian tissue against methotrexate-induced gonadotoxicity: a biochemical, flow cytometric, and histopathological study

  • A Comparison of the Flow Cytometric Analysis Results of Benign and Malignant Serous Tumors of the Ovary

  • Should combined MTX and CoQ10 use be reconsidered in terms of steatosis? A biochemical, flow cytometry, histopathological experimental study

  • Histological and flow cytometric evaluation of astaxanthin’s effects against cyclophosphamide induced heart injury in rats

  • Β Melamine exposure during the weaning period negatively affects ovarian reserve

Conclusion:

Prof. Dr. Yavuz Tekelioğlu is well-qualified and highly suitable for the Best Academic Researcher Award based on his extensive career, strong research leadership, significant scholarly contributions, and educational impact. His focused expertise on toxicology, histology, and cellular analysis is both relevant and impactful.

With strategic enhancements in international collaborations and visibility, he can further solidify his standing as a leading academic researcher. Nonetheless, his current achievements and dedication clearly merit recognition at this level.

Sen Wang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Ms. Sen Wang | Cancer Cell Biology | Best Researcher Award

Ms. Sen Wang , Affiliated Hospital of Jining Medical College , China

Dr. Wang Sen is an accomplished researcher and Deputy Chief Technician at the Affiliated Hospital of Jining Medical University. With a Ph.D. in Pharmaceutical Engineering and a postdoctoral fellowship at Shandong University of Traditional Chinese Medicine, he has developed deep expertise in molecular oncology, tumor microenvironments, and translational medicine. His career spans over a decade, marked by significant research in gastrointestinal and renal cancers, exploring mechanisms of autophagy, endothelial dysfunction, and tumor angiogenesis. Dr. Wang has led and contributed to several prestigious research projects, including National Natural Science Foundation grants. He has published in high-impact journals and holds patents that support translational applications in oncology. Recognized by peers and institutions alike, he received the Shandong Medical Association Youth Science and Technology Award. His work continues to push boundaries in cancer research, demonstrating strong scientific leadership and a commitment to improving therapeutic strategies.

Publication Profile:Β 

Scopus

βœ… Strengths for the Award

  1. Extensive Research Background
    Dr. Wang has demonstrated a consistent and deep involvement in cutting-edge cancer research, especially focusing on tumor microenvironment regulation, autophagy, and angiogenesisβ€”key areas in translational oncology.

  2. Prolific Publication Record
    He is the sole first author of several papers published in high-impact journals like British Journal of Cancer, Cell Death & Disease, and Scientific Reports. These contributions indicate scientific independence and strong writing and experimental skills.

  3. Leadership in Funded Projects
    He has served as Principal Investigator (PI) on multiple prestigious projects, including the NSFC Youth Fund and China Postdoctoral Foundation grants, which testifies to his research leadership and capability in securing competitive funding.

  4. Innovative Impact through Patents
    Dr. Wang is a co-inventor of three Chinese patents, including a novel therapeutic application of MT1G in renal cancerβ€”highlighting a strong translational component in his research.

  5. Academic Awards and Recognition
    His receipt of the Shandong Medical Association Youth Science and Technology Award (Second Prize) in 2024 is an external validation of his scientific excellence at the provincial level.

  6. Collaborative and Interdisciplinary Approach
    His co-authorship with experts across molecular biology, pharmacology, and clinical research demonstrates a collaborative nature crucial for multidisciplinary medical advancements.

πŸ“ˆ Areas for Improvement

  1. International Recognition
    While Dr. Wang’s work is commendable within China, increasing collaboration or recognition on an international level (e.g., international conferences, global research networks) would further elevate his research visibility.

  2. Citations and Real-world Applications
    Some of his recent papers have not yet garnered citations. Continued dissemination, follow-up studies, and clinical application testing will help boost impact.

  3. Expanded Mentorship Role
    There is limited information on his mentorship of young scientists or PhD students. Strengthening academic mentorship could broaden his influence within the scientific community.

πŸŽ“ Education:

Dr. Wang Sen has pursued a comprehensive academic path in life sciences and medical research. He earned his Ph.D. in Pharmaceutical Engineering from Chongqing Medical University (2016–2019), following a Master’s degree in Biochemistry and Molecular Biology at the same institution (2013–2016). His foundational training began with a Bachelor’s degree in Biological Engineering from Jining University (2009–2013), where he laid the groundwork for his interest in molecular biology and drug development. His doctoral and master’s work focused on cancer biology, signaling pathways, and translational medicineβ€”preparing him for cutting-edge postdoctoral research at Shandong University of Traditional Chinese Medicine (2022–2024). This academic journey has equipped him with strong theoretical and experimental skills that he applies in both clinical and laboratory settings.

πŸ§ͺ Experience:

Dr. Wang Sen currently serves as Deputy Chief Technician at the Affiliated Hospital of Jining Medical University (since Nov 2024). Prior to this, he held the role of Chief Technician (2019–2024) at the same hospital, where he led several translational cancer research projects. His responsibilities include designing experimental protocols, overseeing clinical collaboration, and mentoring junior researchers. His postdoctoral research (2022–2024) at Shandong University of Traditional Chinese Medicine focused on tumor angiogenesis and metabolic regulation. Throughout his academic and professional journey, he has shown a keen interest in understanding cancer cell signaling, tumor-endothelial interactions, and the development of therapeutic targets. His multidisciplinary expertise makes him a vital contributor to collaborative projects in molecular medicine and drug discovery.

πŸ† Awards and Honors:

Dr. Wang Sen’s contributions to medical research have earned him notable recognition. In 2024, he received the Shandong Medical Association Youth Science and Technology Award (Second Prize), celebrating his innovative work in cancer biology. He is also a co-inventor on three Chinese patents, including the application of MT1G protein inhibitors for renal cancer and methods related to small molecule metabolite ligands and exosome preparation. These patents demonstrate his commitment to translational research and innovation in therapeutic development. Additionally, his participation in collaborative high-impact publications and national grants has solidified his reputation as a rising leader in biomedical sciences. His academic integrity, technical depth, and consistent contributions to cutting-edge research make him an ideal candidate for recognition through prestigious awards like the Best Researcher Award.

πŸ”¬ Research Focus:

Dr. Wang Sen’s research centers on tumor microenvironment regulation, angiogenesis, autophagy, and tumor stem cell interactions, with a strong focus on gastrointestinal and renal cancers. His work often integrates cellular signaling, exosome biology, and gene expression regulation to understand cancer progression and metastasis. Key interests include pathways involving INSR/FGF5/ADRB2, ALDOC, and MT1G, which he investigates for their roles in tumor metabolism and vascular dynamics. Dr. Wang combines clinical relevance with basic science, aiming to translate molecular findings into diagnostic tools or therapeutic targets. His innovative studies on betulinic acid, p53-mediated pathways, and epigenetic modifications contribute to the broader field of precision oncology. His interdisciplinary approachβ€”bridging pharmacology, molecular biology, and clinical applicationβ€”positions him as a dynamic researcher capable of advancing medical science.

πŸ“š Publications Top Notes:

  1. πŸ“˜ MT1G induces lipid droplet accumulation through H3K14 trimethylation in renal cancer, British Journal of Cancer, 2024 – πŸ₯‡ Sole First Author

  2. πŸ“— p53-mediated autophagy protects against betulinic acid-induced apoptosis in colorectal cancer, Cell Death & Disease, 2017 – πŸ₯‡ Sole First Author

  3. πŸ“• FOXS1 is regulated by GLI1/miR-125a-5p, promotes proliferation and EMT in gastric cancer, Scientific Reports, 2019 – πŸ₯‡ Sole First Author

  4. πŸ“™ Identification of the human HAS3 promoter region, Biochemical and Biophysical Research Communications, 2015 – πŸ₯‡ Sole First Author

  5. πŸ““ Betulinic acid induces G2/M arrest via MT1G in colon cancer cells, Heliyon, 2024 – πŸ‘₯ Co-First Author

  6. πŸ“” PCDH17 induces colorectal cancer metastasis by disrupting vascular barriers, Cell Death and Disease, 2025 – 🧬 Contributor

  7. πŸ“’ OX40 activation drives tumor escape via S1P/YAP angiogenesis, Journal of Clinical Investigation, 2025 – 🧬 Contributor

🧾 Conclusion:

Dr. Wang Sen is a highly qualified and worthy candidate for the Best Researcher Award. His impressive portfolioβ€”spanning publications, funded projects, patents, and recognized awardsβ€”shows that he is not only producing important knowledge but also moving toward real-world application in cancer therapeutics. With continued focus on global engagement and translational outcomes, he is poised to become a leading figure in molecular oncology. His scientific rigor, innovation, and leadership embody the spirit of this award.

Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Dominique Heymann | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Dominique Heymann , Nantes UniversitΓ©, CNRS, Institut de CancΓ©rologie de l”Ouest , France

Professor Dominique Heymann is a highly esteemed academic and clinician, specializing in histology, embryology, and oncology. He is a Professor at Nantes University, France, and a Hospital Practitioner at the ICO Cancer Centre. With a wealth of experience in bone oncology and cancer research, he is also an Honorary Professor at the University of Sheffield, UK. His expertise spans from cell biology to immunology and biochemistry, and he is dedicated to advancing cancer research, particularly in the field of bone tumors and osteosarcoma. With numerous publications to his name and contributions to the global scientific community, Professor Heymann is recognized for his groundbreaking work in cell signaling and tumor progression. He is a valued researcher in the oncology community, with a strong focus on developing innovative therapies for cancer treatment.

Publication Profile:

Google Scholar

Strengths for the Award:

Professor Dominique Heymann is a distinguished figure in the field of oncology, particularly bone oncology, with a strong focus on the molecular mechanisms of bone tumors like osteosarcoma. His academic and clinical roles at the University of Nantes and the ICO Cancer Centre underscore his leadership in research and patient care. He has contributed significantly to understanding tumor biology, bone remodeling, and regenerative medicine, making him a highly respected expert in these fields. His research addresses crucial topics such as circulating tumor cells, targeted therapies, and the development of new anticancer agents, all of which are of immense value to advancing cancer treatment. With multiple publications in prestigious journals, including studies on novel therapies and molecular pathways in cancer progression, Professor Heymann has demonstrated exceptional scientific rigor. His global collaborations and recognition further establish him as a leading researcher in cancer biology and oncology.

Areas for Improvements:

Despite his numerous contributions, there are a few areas where Professor Heymann’s research could evolve. While he has made notable strides in cancer treatment and bone oncology, expanding research into more personalized medicine approaches and exploring the integration of AI and machine learning in predictive oncology could enhance the applicability of his findings. Furthermore, increasing collaborative efforts with international interdisciplinary teams could yield broader insights, especially in rare cancers and metastasis research. Developing a more extensive outreach to clinical trials and collaborations in broader regions may also allow for faster translation of his research into practice.

Education:

Professor Heymann began his academic journey at Paris VII University, where he earned a Master’s degree in Cell Biology in 1991. His PhD in Cell Biology and Immunology was completed at Nantes University in 1995, a pivotal moment in his career. Further expanding his knowledge, he pursued research management abilities and a deeper focus on Biochemistry and Cell Biology at Nantes University in 1998. He also received specialized certification in Histology from Nantes University in 1999 and later completed the required authorizations for animal experimentation in 2003 and 2016. Throughout his academic career, Professor Heymann has continually updated his qualifications, ensuring his expertise remains at the cutting edge of medical and biological sciences. His academic foundation has underpinned his significant contributions to cancer research, with a strong emphasis on bone oncology and regenerative medicine.

Experience:

Professor Dominique Heymann has an extensive and diverse career spanning several decades in both academic and clinical settings. Currently, he serves as a Professor of Histology/Embryology at Nantes University and as a Hospital Practitioner at the ICO Cancer Centre, where he is instrumental in patient care and research. His professional trajectory includes significant roles in oncology, particularly focused on bone tumors, osteosarcoma, and regenerative medicine. As an Honorary Professor at the University of Sheffield, he extends his influence beyond France, fostering international collaboration in cancer research. Professor Heymann has been a prominent figure in multiple research projects, having managed and contributed to groundbreaking studies. His expertise in cancer biology, combined with his academic roles, has allowed him to mentor students and researchers, shaping the next generation of scientists. His dual role in academia and clinical practice makes him a leading figure in both spheres.

Awards and Honors:

Professor Dominique Heymann’s career is adorned with numerous accolades and honors. As a tenured professor at the University of Nantes, he has received recognition for his contributions to histology, embryology, and oncology. He was appointed as an Honorary Professor in Bone Oncology at the University of Sheffield, UK, an esteemed acknowledgment of his expertise in the field. His work in cancer research, particularly related to bone tumors, has earned him international recognition, and his published studies continue to be highly regarded in scientific journals. Additionally, Professor Heymann has contributed significantly to the understanding of osteosarcoma and bone regeneration, which has earned him awards from academic and clinical societies. His continuous impact in advancing the field through groundbreaking research, leadership in clinical oncology, and educational contributions has made him a highly respected figure in the medical and scientific communities.

Research Focus:

Professor Dominique Heymann’s research is focused on cancer, particularly bone tumors such as osteosarcoma, and the molecular mechanisms involved in bone regeneration. His work primarily investigates the signaling pathways that control bone remodeling, the interactions between tumor cells and the microenvironment, and the role of immune responses in bone diseases. One of his key research interests is the development of targeted therapies to combat cancer progression, with a special emphasis on novel anticancer agents, including glycosaminoglycan-mimetic compounds derived from marine bacterial exopolysaccharides. In addition, Professor Heymann is dedicated to studying the role of circulating tumor cells as predictive markers for drug resistance and tumor progression. His expertise also includes stem cell therapies, autophagy in osteoblasts, and the potential for therapeutic applications in bone repair and regeneration. His research aims to improve patient outcomes through innovative approaches in cancer treatment and bone health.

Publications Top Notes:

  • Heymann D, MuΓ±oz-Garcia J, Babuty A, et al. A new promising anticancer agent: a glycosaminoglycan-mimetic derived from the marine bacterial infernan exopolysaccharide. Int J Biol Macromol. (in press) 🧬

  • Jacquot P, MuΓ±oz-Garcia J, LΓ©ger A, et al. A multispecific checkpoint inhibitor Nanofitin with a fast tumor accumulation property and antitumor activity in immune competent mice. Biomolecules. (in press) πŸ”¬

  • Yadav P, Heymann D, Prasad RN. Circulating tumor cells: a predictive marker for drug resistance and tumor progression. Front Oncol. (in press) πŸ”¬

  • MuΓ±oz-Garcia J, et al. Interleukin-34 orchestrates bone formation through its binding to Bone Morphogenic Proteins. Theranostics. 2025; 15(7):3185-3202. 🦴

  • Young RJ, et al. CIRCUS: CIRCUlating tumor cells in soft tissue Sarcoma – a short report. Cancer Drug Resist. 2022; 4:51. πŸ’‰

  • Oliver L, et al. Transcriptional landscape of the interaction of human mesenchymal stem cells with glioblastoma in bioprinted co-cultures. Stem Cell Res Ther. 2024; 15(1):424. 🧫

  • Cordova LA, et al. Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care? Osteoporos Int. 2024; 35(9):1677-1678. 🦷

  • Childs A, et al. A prospective observational cohort study for newly diagnosed patients in the UK: ICONIC study initial results. Cancers (Basel). 2024; 16(13):2351. πŸ“Š

  • Rey V, et al. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma. EBioMedicine. 2024; 102:105090. 🧬

  • Jubelin C, et al. Identification of MCM4 and PKRDC as new regulators of osteosarcoma cell dormancy based on 3D cultures. BBA Mol Cell Res. 2024; 1871:119660. πŸ§ͺ

Conclusion:

Professor Dominique Heymann’s expertise in oncology, histology, and embryology positions him as an outstanding candidate for the Research for Best Researcher Award. His achievements in cancer research, particularly in bone tumors, and his contributions to advancing the understanding of tumor biology make him an exemplary figure. While there are areas to expand in terms of interdisciplinary collaborations and technological integration, his exceptional body of work and his dedication to both academic excellence and clinical practice make him a deserving candidate for this prestigious award.

Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Ana Figueiras , Faculty of Pharmacy/University of Coimbra , Portugal

Ana Rita Ramalho Figueiras is an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, Portugal, and a researcher at REQUIMTE/LAQV, focusing on Pharmaceutical Technology. She earned her PhD in Pharmaceutics from the University of Coimbra in 2009, specializing in drug delivery systems, particularly for cancer treatments. Throughout her career, Ana has worked on advancing the development of block copolymers and micellar systems for targeted drug delivery. With a strong academic background and international exposure, she has contributed significantly to the fields of pharmaceutics, drug formulation, and pharmaceutical sciences. Ana’s work has been recognized through various publications in top journals, and she is deeply involved in mentoring post-doctoral researchers. Her expertise and leadership in pharmaceutical research continue to influence the development of innovative therapies in the pharmaceutical field.

Publication Profile:Β 

Orcid

Strengths for the Award:

Ana Rita Ramalho Figueiras is a highly accomplished researcher in pharmaceutical sciences, with extensive contributions to drug delivery systems, particularly focusing on micellar systems and polymeric micelles for cancer therapy. Her interdisciplinary work bridges pharmaceutics, chemistry, and biomedicine, showcasing her ability to innovate within drug delivery mechanisms for complex diseases. As an Assistant Professor at the University of Coimbra and an integrated member of the REQUIMTE/LAQV research group, she brings a wealth of academic and research leadership to her field.

Her innovative contributions have been recognized with various academic awards, including distinctions for oral communications and publications. Additionally, she has made substantial contributions to numerous collaborative research projects, focusing on the development of novel therapeutic strategies and drug delivery systems that target poorly soluble drugs, cancer therapies, and chronic diseases like Alzheimer’s.

Areas for Improvement:

While Figueiras is a leading figure in the scientific community, expanding her outreach to a broader range of international research collaborations could further amplify her impact. Although her work on drug delivery systems has significant potential for clinical applications, there could be further focus on translating her findings from bench to bedside by collaborating with clinical researchers for clinical trials and regulatory studies. A stronger emphasis on commercialization of her research could also be beneficial for broader societal impact.

Education:

Ana Rita Ramalho Figueiras pursued her academic journey in the field of Pharmaceutical Sciences, beginning at the University of Coimbra in Portugal. She graduated with a degree in Pharmaceutical Sciences in 2002, followed by a PhD in Pharmaceutics at the same university in 2009. Her doctoral research was focused on enhancing drug solubility and permeability, with a specific focus on cyclodextrins and mucoadhesive polymers for buccal drug delivery. During her PhD, she gained international exposure by collaborating with the University of Santiago de Compostela, Spain, and the University of Innsbruck, Austria. She is also registered as a member of the Ordem dos FarmacΓͺuticos in Portugal since 2003. Ana’s educational foundation, combined with her interdisciplinary collaborations, has provided her with a robust understanding of pharmaceutical sciences and technologies, forming the cornerstone of her impactful career in academia and research.

Experience:

Ana Rita Ramalho Figueiras has been an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, since September 2014, where she is an integrated Ph.D. member in the Pharmaceutical Technology group of REQUIMTE/LAQV. Prior to this, she was an Invited Assistant Professor from 2013 to 2014, working closely with the Center of Neuroscience and Cell Biology (CNC/UC) and contributing as a collaborator in the Health Sciences Research Centre (CICS/UBI). Her academic roles involve teaching, mentoring students and postdoctoral fellows, and leading research projects on advanced drug delivery systems. She has also been involved in supervising several postdoctoral researchers, focusing on developing and characterizing polymeric micellar systems and controlled delivery systems for drugs like pilocarpine. Throughout her career, Ana has participated in various scientific projects, bringing valuable insights into the design of innovative drug delivery platforms with applications in cancer therapy and other medical conditions.

Awards and Honors:

Ana Rita Ramalho Figueiras has received several accolades for her research excellence and contributions to the field of Pharmaceutical Sciences. In 2004, she was awarded a prestigious PhD fellowship by Fundação para a CiΓͺncia e Tecnologia (FCT), which enabled her to pursue her doctoral studies. In 2011, she received the Best Short Communication Award at the VI Annual CICS Symposium for her work on new therapeutic strategies for siRNA delivery. In 2012, she was honored with the Best Oral Communication Award for her research on Poloxamine-Ξ±-cyclodextrin supramolecular gels promoting osteogenic differentiation of mesenchymal stem cells. These awards underscore her commitment to scientific advancement, as she continues to lead innovative research in drug delivery systems, nanomedicine, and cancer therapy. Ana’s dedication to advancing pharmaceutics has also led her to mentor future generations of researchers, further solidifying her reputation as a leading academic in her field.

Research Focus:

Ana Rita Ramalho Figueiras focuses her research on developing advanced drug delivery systems, specifically in the context of cancer therapies. Her primary research interest lies in utilizing block copolymers and micellar systems for targeted and controlled drug release. This includes the formulation of poorly water-soluble drugs, improving their bioavailability, and creating novel pharmaceutical formulations for effective treatment. Ana is particularly interested in the development of polymeric micelles for the delivery of therapeutic agents, including drugs and genes, to treat various diseases, with a strong emphasis on oncology. Additionally, her research investigates the use of mucoadhesive polymers for drug delivery to mucosal surfaces. With a commitment to improving drug efficacy and reducing side effects, her work aims to enhance patient outcomes through innovative drug formulations. Ana is also involved in several projects that explore natural compounds and their potential for pharmaceutical applications, further contributing to advancements in the drug delivery and pharmaceutical fields.

Publications Top Notes:

  1. “Unraveling Rosmarinic Acid Anticancer Mechanisms in Oral Cancer Malignant Transformation” πŸŽ—οΈπŸ¦·
  2. “Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts” πŸ’„βš–οΈ
  3. “The Many Faces of Cyclodextrins within Self-Assembling Polymer Nanovehicles: From Inclusion Complexes to Valuable Structural and Functional Elements” πŸ”¬πŸ§ͺ
  4. “Development and Characterization of Curcumin-Loaded TPGS/F127/P123 Polymeric Micelles as a Potential Therapy for Colorectal Cancer” πŸ‚βš•οΈ
  5. “Pulmonary Delivery of Bacterial Lysates Mediated by Locust Bean Gum Microparticles” 🌬️🦠
  6. “Non-Toxic Mucoadhesive Locust Bean Gum Microparticles for Delivery of Bacterial Lysates to Prevent Respiratory Diseases” 🌱🫁
  7. “Polymersomes as the Next Attractive Generation of Drug Delivery Systems: Definition, Synthesis and Applications” πŸ§«πŸ’Š
  8. “Nanotheranostics: The Afterglow for Cancer Immunotherapy” πŸ’‘πŸ’‰
  9. “Acanthus Mollis Formulations for Transdermal Delivery: From Hydrogels to Emulsions” πŸŒΏπŸ’§
  10. “A Review of the Application of Ganoderma Lucidum (Curtis) P. Karst. in Nanotechnology for the Treatment of Cancer” πŸ„πŸ’»

Conclusion:

Ana Figueiras’ expertise in pharmaceutical technology, particularly in the development of polymeric micelles for drug delivery, marks her as an outstanding candidate for the Best Researcher Award. She is an exemplary figure in the realm of pharmaceutics with a strong research focus on improving drug therapies for cancer and other severe diseases. Her work continues to advance drug delivery systems, paving the way for future medical breakthroughs. Figueiras demonstrates a strong foundation in academic excellence, research innovation, and collaboration, positioning her as a leader in her field.

Li Hou | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Li Hou | Cancer Cell Biology | Best Researcher Award

Prof. Li Hou , Department of Oncology and Hematology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China

Li Hou is a distinguished Chief Physician and Director of the Hematology and Oncology Department at Dongzhimen Hospital, affiliated with Beijing University of Chinese Medicine. With a career spanning over 30 years, she has made remarkable contributions in the integration of Traditional Chinese Medicine (TCM) and Western Medicine for treating tumors and blood diseases. A renowned researcher and educator, Hou Li has led over 40 research projects, authored 50+ papers, and published significant work on tumor and blood disease therapies. Her expertise has been recognized with the prestigious “Famous Doctor’s Excellent Demeanor Award” in 2018. Her passion for advancing healthcare through combined approaches has made her a leader in oncology and hematology in China and internationally. πŸŒŸπŸŽ“πŸ’‰

Publication Profile:

Orcid

Strengths for the Award:

Dr. Li Hou is highly deserving of the Best Researcher Award due to her exceptional contributions in integrating Traditional Chinese Medicine (TCM) and Western Medicine for the treatment of hematological diseases and cancers. Her career is distinguished by over 40 research programs and more than 50 published papers, demonstrating her expertise in oncology and hematology. She has authored notable articles in high-impact journals, showcasing her deep understanding of tumor biology and blood disorders. Her leadership in research, coupled with her clinical practice, has led to groundbreaking insights into the treatment of malignancies, including her work on identifying novel drug targets for cancers. Furthermore, her role in academia and professional service, as a key figure in several influential medical associations, highlights her outstanding impact in the medical field. πŸŒŸπŸ§‘β€πŸ”¬πŸ“š

Areas for Improvement:

While Dr. Li Hou research achievements are commendable, expanding her research collaborations internationally could further enhance her impact. Engaging with global research communities may foster new perspectives and facilitate the exchange of ideas, particularly in the context of cutting-edge medical technologies. Additionally, expanding research into the long-term outcomes of integrated therapies in various populations could provide further evidence of the benefits of combining TCM with Western approaches. This would allow her work to gain even more recognition and clinical application worldwide. πŸŒπŸ”¬

Education:

Li Hou completed her Bachelor’s in Chinese Medicine at Beijing University of Chinese Medicine in 1993. She then pursued her Master’s degree in Integrated Chinese and Western Medicine from the same institution, completing it in 1998. In 2004, she earned her Doctorate in Integrated Chinese and Western Medicine. Her academic journey has been rooted in the application of both traditional and modern methods to treat complex diseases like cancer and blood disorders, providing her with a strong foundation for her career in clinical practice, research, and education. πŸŽ“πŸ“šπŸ©Ί

Experience:

Li Hou clinical career began in 1993 as a resident at Dongzhimen Hospital. By 1999, she advanced to attending physician, and by 2008, she became an associate chief physician. In 2013, she was appointed as Chief Physician at Dongzhimen Hospital, where she has been working ever since. She holds significant leadership roles within the field, including Chairman of several prestigious oncology committees. Additionally, her role as an evaluation expert for the National Natural Science Foundation of China demonstrates her expertise in research. She has been instrumental in combining traditional Chinese medicine with modern treatments in the management of cancer and hematological conditions. πŸ₯πŸ’ΌπŸ‘©β€βš•οΈ

Research Focus:

Li Hou research focus revolves around the integration of Traditional Chinese Medicine (TCM) and Western medicine to treat hematological diseases and cancer. She has made significant strides in identifying novel therapeutic approaches, with an emphasis on improving cancer treatment outcomes. Her work includes studying the role of TCM in modulating drug responses and enhancing chemotherapy effectiveness. Through her extensive research, she has contributed to understanding the genetic and molecular mechanisms involved in blood cancer and tumor progression, aiming to optimize patient care and survival rates. Her studies have been published in leading medical journals. πŸ§¬πŸ”¬πŸ’‘

Publications Top Notes:

  • Identification of potential drug targets for four site-specific cancers by integrating human plasma proteome with genome – Journal of Pharmaceutical and Biomedical Analysis (2025)
  • Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia – Computers in Biology and Medicine (2024)
  • Genetically predicted 486 blood metabolites in relation to risk of colorectal cancer: A Mendelian randomization study – Cancer Medicine (2023)
  • Improvement of Early Death in Acute Promyelocytic Leukemia: A Population-Based Analysis – Clinical Lymphoma Myeloma and Leukemia (2023)
  • Tanshinone IIa Induces Autophagy and Apoptosis via PI3K/Akt/mTOR Axis in Acute Promyelocytic Leukemia NB4 Cells – Evidence-Based Complementary and Alternative Medicine (2021)
  • Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial – Pain Research and Management (2020) πŸ“πŸ“šπŸŽ―

Conclusion:

Dr. Li Hou contributions to medicine are profound and multifaceted, blending traditional and modern therapeutic approaches to offer innovative solutions for cancer and blood diseases. Her research has not only advanced scientific knowledge but also improved patient care. As a leader in both clinical practice and research, she exemplifies the qualities of a Best Researcher Award recipient. Through her continued dedication to her work, Dr. Hou Li will undoubtedly remain at the forefront of medical research, driving progress in both China and globally. πŸ†πŸ’‰πŸ©Ί